Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs

INTRODUCTION: This open-label study evaluated the immunogenicity, safety, and efficacy of sarilumab monotherapy in patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response or intolerance to prior conventional synthetic disease-modifying antirheumatic drugs. METHODS:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Rheumatol Ther
Main Authors: Wells, Alvin F., Parrino, Janie, Mangan, Erin K., Paccaly, Anne, Lin, Yong, Xu, Christine, Fan, Chunpeng, Graham, Neil M. H., van Hoogstraten, Hubert, Torri, Albert
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6702535/
https://ncbi.nlm.nih.gov/pubmed/31090044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-019-0157-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados